Maesaka F - Search Results

1

Hypomethylation of CLDN4 Gene Promoter Is Associated with Malignant Phenotype in Urinary Bladder Cancer.

Maesaka F, Kuwada M, Horii S, Kishi S, Fujiwara-Tani R, Mori S, Fujii K, Mori T, Ohmori H, Owari T, Miyake M, Nakai Y, Tanaka N, Bhawal UK, Luo Y, Kondoh M, Fujimoto K, Kuniyasu H. Maesaka F, et al. Int J Mol Sci. 2022 Jun 10;23(12):6516. doi: 10.3390/ijms23126516. Int J Mol Sci. 2022. PMID: 35742959 Free PMC article.

2

[A Case of Rheumatoid Arthritis Developed during Treatment with Nivolumab for Renal Cell Carcinoma].

Tomizawa M, Nakai Y, Maesaka F, Owari T, Hara R, Miyake M, Inoue T, Anai S, Tanaka N, Fujimoto K. Tomizawa M, et al. Among authors: maesaka f. Hinyokika Kiyo. 2018 Oct;64(10):397-401. doi: 10.14989/ActaUrolJap_64_10_397. Hinyokika Kiyo. 2018. PMID: 30543737 Free article. Review. Japanese.

3

Amrubicin is effective against small cell carcinoma of the prostate as a second-line chemotherapeutic agent: A case report.

Maesaka F, Nakai Y, Tomizawa M, Owari T, Miyake M, Inoue T, Anai S, Tanaka N, Fujimoto K. Maesaka F, et al. IJU Case Rep. 2019 Mar 7;2(3):133-136. doi: 10.1002/iju5.12058. eCollection 2019 May. IJU Case Rep. 2019. PMID: 32743393 Free PMC article.

4

Impact of neoadjuvant androgen deprivation therapy on postimplant prostate D90 and prostate volume after low-dose-rate brachytherapy for localized prostate cancer.

Owari T, Tanaka N, Nakai Y, Miyake M, Anai S, Torimoto K, Maesaka F, Asakawa I, Yamaki K, Fuji T, Hasegawa M, Fujimoto K. Owari T, et al. Among authors: maesaka f. Int J Urol. 2022 Feb;29(2):143-151. doi: 10.1111/iju.14738. Epub 2021 Nov 11. Int J Urol. 2022. PMID: 34763369

5

Evaluating the optimal technique of transperineal template-guided saturation biopsy in patients requiring repeat prostate biopsy.

Nakai Y, Tanaka N, Maesaka F, Miyake M, Fujii T, Fujimoto K. Nakai Y, et al. Among authors: maesaka f. Int J Urol. 2020 Dec;27(12):1157-1158. doi: 10.1111/iju.14373. Epub 2020 Sep 17. Int J Urol. 2020. PMID: 32939819 No abstract available.

6

Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.

Maesaka F, Tanaka N, Nakai Y, Asakawa I, Tomizawa M, Owari T, Miyake M, Anai S, Yamaki K, Fujii T, Hasegawa M, Fujimoto K. Maesaka F, et al. Int J Urol. 2021 Nov;28(11):1171-1176. doi: 10.1111/iju.14667. Epub 2021 Aug 10. Int J Urol. 2021. PMID: 34378247 Clinical Trial.

7

Unexpected presentation of allograft dysfunction triggered by page kidney phenomenon immediately after kidney transplantation: a case report.

Hori S, Tomizawa M, Maesaka F, Owari T, Morizawa Y, Nakai Y, Miyake M, Yoneda T, Tanaka N, Yoshida K, Fujimoto K. Hori S, et al. Among authors: maesaka f. BMC Nephrol. 2018 Mar 13;19(1):59. doi: 10.1186/s12882-018-0860-2. BMC Nephrol. 2018. PMID: 29534686 Free PMC article.

8

A Potential Application of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Combined with Photodynamic Diagnosis for the Detection of Bladder Carcinoma in Situ: Toward the Future 'MRI-PDD Fusion TURBT'.

Miyake M, Maesaka F, Marugami N, Miyamoto T, Nakai Y, Ohnishi S, Gotoh D, Owari T, Hori S, Morizawa Y, Itami Y, Inoue T, Anai S, Torimoto K, Fujii T, Shimada K, Tanaka N, Fujimoto K. Miyake M, et al. Among authors: maesaka f. Diagnostics (Basel). 2019 Sep 4;9(3):112. doi: 10.3390/diagnostics9030112. Diagnostics (Basel). 2019. PMID: 31487881 Free PMC article.

9

Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.

Miyake M, Shimizu T, Nishimura N, Kiba K, Maesaka F, Oda Y, Tachibana A, Tomizawa M, Ohmori C, Matsumura Y, Ichikawa K, Mizobuchi S, Yoshikawa T, Hori S, Morizawa Y, Gotoh D, Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group. Miyake M, et al. Among authors: maesaka f. Clin Genitourin Cancer. 2022 Apr;20(2):196.e1-196.e9. doi: 10.1016/j.clgc.2021.11.006. Epub 2021 Nov 15. Clin Genitourin Cancer. 2022. PMID: 34916166

10

External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracy.

Owari T, Miyake M, Nakai Y, Tanaka N, Itami Y, Hirao S, Momose H, Nakagawa Y, Iida K, Maesaka F, Shimizu T, Iemura Y, Matsumoto Y, Kuwada M, Otani T, Otsuka K, Okajima E, Hosokawa Y, Okamura R, Fujimoto K. Owari T, et al. Among authors: maesaka f. J Bone Oncol. 2020 Dec 13;26:100344. doi: 10.1016/j.jbo.2020.100344. eCollection 2021 Feb. J Bone Oncol. 2020. PMID: 33384916 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page